Shilpa Medicare Limited

NSE SHILPAMED.NS

Shilpa Medicare Limited EBITDA Margin for the year ending March 31, 2024: 21.33%

Shilpa Medicare Limited EBITDA Margin is 21.33% for the year ending March 31, 2024, a 87.14% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Shilpa Medicare Limited EBITDA Margin for the year ending March 31, 2023 was 11.40%, a -42.73% change year over year.
  • Shilpa Medicare Limited EBITDA Margin for the year ending March 31, 2022 was 19.90%, a -34.29% change year over year.
  • Shilpa Medicare Limited EBITDA Margin for the year ending March 31, 2021 was 30.29%, a 15.00% change year over year.
  • Shilpa Medicare Limited EBITDA Margin for the year ending March 31, 2020 was 26.34%, a -2.24% change year over year.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
SV Wall Street
NSE: SHILPAMED.NS

Shilpa Medicare Limited

CEO Mr. Vishnukanth Chaturbhuj Bhutada B. Pharm
IPO Date Dec. 3, 2009
Location India
Headquarters Shilpa House
Employees 1,007
Sector Health Care
Industries
Pharmaceuticals
Description

Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (API's), intermediates, and formulations in India, the United States, Europe, and internationally. It offers oncology and non-oncology API's.; and new drug delivery systems, peptides/biotech products, specialty chemicals, etc. The company also provides contract manufacturing of various dosage forms, such as tablets, capsules, liquid injections, lyophilized injectables, and sterile dry powder injectables. It is also involved in the wind power generation activities. Shilpa Medicare Limited was incorporated in 1987 and is headquartered in Raichur, India.

StockViz Staff

February 1, 2025

Any question? Send us an email